Literature DB >> 15003289

Temporal and topographic profiles of cyclooxygenase-2 expression during 24 h of focal brain ishemia in rats.

Chiaki Yokota1, Tomohito Kaji, Yuji Kuge, Hiroyasu Inoue, Nagara Tamaki, Kazuo Minematsu.   

Abstract

Substantial increases in cyclooxygenase-2 (COX-2) mRNA and protein levels were demonstrated in the peri-infarct and focal ischemic areas after 3-24 and 12-24 h, respectively, in rats. In the ischemic core, significant increases in COX-2 mRNA followed 6 h of ischemia, though the peak level was about one-third of that in the peri-infarct area. Increases in COX-2 protein in the ischemic core were not observed during ischemic periods. Diffuse, neuronal COX-2 staining was found in peri-infarct areas as well as in discrete, immunoreactive neurons in the ischemic core. Robust increases in prostaglandin E2 levels in the peri-infarct area were demonstrated following 24 h of ischemia. Prostaglandin production as well as COX-2 expression in ischemic tissues depended on the degree and duration of the reduction in cerebral blood flow.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003289     DOI: 10.1016/j.neulet.2003.12.109

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Piperine suppresses cerebral ischemia-reperfusion-induced inflammation through the repression of COX-2, NOS-2, and NF-κB in middle cerebral artery occlusion rat model.

Authors:  Kumar Vaibhav; Pallavi Shrivastava; Hayate Javed; Andleeb Khan; Md Ejaz Ahmed; Rizwana Tabassum; Mohd Moshahid Khan; Gulrana Khuwaja; Farah Islam; M Saeed Siddiqui; Mohammed M Safhi; Fakhrul Islam
Journal:  Mol Cell Biochem       Date:  2012-06-06       Impact factor: 3.396

2.  Protective effects of perfluorooctyl-bromide nanoparticles on early brain injuries following subarachnoid hemorrhage in rats.

Authors:  Huan Zhang; Rui Xu; Fei Xie; Wei Xu; Meng-Fei Zeng; Xin Wang; Ji Zhu
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

Review 3.  Rodent models of focal stroke: size, mechanism, and purpose.

Authors:  S Thomas Carmichael
Journal:  NeuroRx       Date:  2005-07

4.  Inflammation in adult and neonatal stroke.

Authors:  Zinaida S Vexler; Xian Nan Tang; Midori A Yenari
Journal:  Clin Neurosci Res       Date:  2006-12-01

5.  Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury.

Authors:  Yuri Ikeda-Matsuo; Azusa Ota; Tetsuya Fukada; Satoshi Uematsu; Shizuo Akira; Yasuharu Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

6.  Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity.

Authors:  Y Ikeda-Matsuo; Y Hirayama; A Ota; S Uematsu; S Akira; Y Sasaki
Journal:  Br J Pharmacol       Date:  2010-01-29       Impact factor: 8.739

Review 7.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

8.  Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia.

Authors:  Tatsurou Yagami
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

9.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  NF-kappaB induces PGE2-synthesizing enzymes in neurons.

Authors:  Waleed Barakat; Oliver Herrmann; Bernd Baumann; Markus Schwaninger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-05-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.